Company intelligence / Profile preview
Invictus Oncology
- Ownership
- Private
- Employees
- ~14
- Development stage
- Preclinical
Overview
Invictus Oncology develops novel anticancer therapeutics with a primary focus on triple negative breast cancer. Its pipeline includes next-generation platinum-based chemotherapies designed to improve efficacy and reduce side effects, as well as antibody-drug conjugates using proprietary linker technology aimed at minimizing damage to healthy tissue. The company collaborates with academic institutions, industry partners, and hospitals in India. No published pivotal clinical results are available; the company remains in early clinical development.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (platinum-based chemotherapies)Antibody-drug conjugates (ADCs)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Invictus Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Invictus Oncology.